Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Syndax PharmaceuticalsFRA:1T3 +3.34%28 Debt-to-Equity is 39.03 as of Jun. 2026, which is 130000% above its 10-year median of 0.03. GuruFocus rates FRA:1T3 with a GF Score™ of 28/100. The stock has 5 warning signs investors should review. Among 963 Biotechnology companies, Syndax Pharmaceuticals ranks worse than 99.79% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Syndax Pharmaceuticals's Debt-to-Equity or its related term are showing as below:
FRA:1T3'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.03 Max: 39.04
Current: 39.04
During the past 13 years, the highest Debt-to-Equity Ratio of Syndax Pharmaceuticals was 39.04. The lowest was 0.00. And the median was 0.03.
FRA:1T3's Debt-to-Equity is ranked worse than 99.79% of 963
companies
in the Biotechnology industry
Industry Median: 0.16
vs FRA:1T3: 39.04
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Syndax Pharmaceuticals Debt-to-Equity Related Terms
Syndax Pharmaceuticals Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Syndax Pharmaceuticals's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1T3 vs FTRE, DMRA, RXRX: Debt-to-Equity Comparison
For the Biotechnology subindustry, Syndax Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syndax Pharmaceuticals Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Syndax Pharmaceuticals's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Syndax Pharmaceuticals's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Syndax Pharmaceuticals (FRA:1T3) has a Debt-to-Equity of 39.03 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Syndax Pharmaceuticals and its competitors. This is 130000% above median its historical median of 0.03. According to the industry distribution chart, Syndax Pharmaceuticals ranks #961 out of 963 companies in the Biotechnology industry, placing it in the top 99.8%.
Is Syndax Pharmaceuticals' Debt-to-Equity too high?
Syndax Pharmaceuticals' current Debt-to-Equity of 39.03 is 130000% above median its 10-year median of 0.03. The Biotechnology industry median Debt-to-Equity is 0.16. Syndax Pharmaceuticals' value of 39.03 is 24293.8% above this industry median. Based on the distribution chart, Syndax Pharmaceuticals ranks #961 out of 963 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Syndax Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Syndax Pharmaceuticals' Debt-to-Equity compare to FTRE and DMRA?
According to the Biotechnology industry distribution chart, Syndax Pharmaceuticals ranks #961 out of 963 companies for Debt-to-Equity. This places Syndax Pharmaceuticals in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Syndax Pharmaceuticals' value of 39.03 is 24293.8% above this benchmark. While the company's 10-year median is 0.03 vs. the industry median of 0.16, Syndax Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Syndax Pharmaceuticals's current Debt-to-Equity of 39.03 is 24293.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Syndax Pharmaceuticals and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Syndax Pharmaceuticals's current Debt-to-Equity is 39.03, which is 130000% above median its own 10-year median of 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syndax Pharmaceuticals stock overvalued right now?
Syndax Pharmaceuticals (FRA:1T3) has a current Debt-to-Equity of 39.03. The current Debt-to-Equity is 39.03, which is 130000% above median its 10-year median of 0.03 and 24293.8% above the Biotechnology industry median of 0.16. Syndax Pharmaceuticals' overall GF Score™ is 28/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Syndax Pharmaceuticals (FRA:1T3), the current Debt-to-Equity is 39.03 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
28GF Score
Get the complete analysis for FRA:1T3
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1T3 has been successfully added to your 
